Loading…

Molecular biomarkers for future screening of lung cancer

The Landmark National Lung Screening Trial established the potential for low dose CT screening (LDCT) to reduce lung cancer‐specific mortality in high‐risk patients as defined by smoking history and age. However, the prevalence of lung cancer in asymptomatic smokers selected based on the NLST criter...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2013-10, Vol.108 (5), p.327-333
Main Authors: Hensing, Thomas A., Salgia, Ravi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Landmark National Lung Screening Trial established the potential for low dose CT screening (LDCT) to reduce lung cancer‐specific mortality in high‐risk patients as defined by smoking history and age. However, the prevalence of lung cancer in asymptomatic smokers selected based on the NLST criteria is low. Recent advances have facilitated biomarker discovery for early diagnosis of lung cancer through the analysis of surrogate tissues, including airway epithelium, sputum, exhaled breath, and blood. Although a number of candidate diagnostic biomarkers have been described, none have been validated for use in the clinical setting. The NLST ACRIN biomarker repository is a valuable resource of annotated biological specimens that were collected during the NLST trial, which has the potential to facilitate validation of candidate biomarkers for early diagnosis identified in discovery trials. It will be important to perform retrospective and prospective analysis of biomarkers to screen for lung cancer. The review below summarizes some of our understanding of biomarkers in screening. J. Surg. Oncol. 2013;108:327–333. © 2013 Wiley Periodicals, Inc.
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.23382